David Avigan
Clinical trials sponsored by David Avigan, explained in plain language.
-
New vaccine boosts CAR-T power against bone marrow cancer
Disease control Recruiting nowThis early-stage trial tests whether adding a personalized cancer vaccine (made from a patient's own immune cells and tumor cells) to standard CAR-T cell therapy can safely improve outcomes for people with multiple myeloma that has returned or stopped responding to treatment. Abo…
Phase: PHASE1 • Sponsor: David Avigan • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New Vaccine-Drug combo takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis early-phase study tests whether combining a personalized cancer vaccine (made from a patient's own tumor and immune cells) with the drug elranatamab is safe and feasible for people with multiple myeloma that has returned or stopped responding to prior treatments. Up to 25 pa…
Phase: PHASE1 • Sponsor: David Avigan • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental T-Cell combo targets Hard-to-Treat leukemia
Disease control Recruiting nowThis early-phase trial is testing a new approach for acute myeloid leukemia (AML) that combines a personalized vaccine made from the patient's own immune and leukemia cells, specially trained T-cells, and two standard chemotherapy drugs. The study aims to see if this combination …
Phase: PHASE1 • Sponsor: David Avigan • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC